APUS (Apimeds Pharmaceuticals Us) Beginning Cash Position: $9.64 Mil (As of Mar. 2026)


APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.72
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us Beginning Cash Position?

Apimeds Pharmaceuticals Us APUS -2.04% 14 Beginning Cash Position is $9.64 Mil as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Apimeds Pharmaceuticals Us's Beginning Cash Position for the quarter that ended in Mar. 2026 was $9.64 Mil.

Apimeds Pharmaceuticals Us's quarterly Beginning Cash Position increased from Sep. 2025 ($8.74 Mil) to Dec. 2025 ($14.99 Mil) but then declined from Dec. 2025 ($14.99 Mil) to Mar. 2026 ($9.64 Mil).

Apimeds Pharmaceuticals Us's annual Beginning Cash Position increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.41 Mil) and increased from Dec. 2024 ($0.41 Mil) to Dec. 2025 ($8.00 Mil).

Apimeds Pharmaceuticals Us Beginning Cash Position Related Terms

Apimeds Pharmaceuticals Us Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us Beginning Cash Position Chart

Apimeds Pharmaceuticals Us Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
0.59 0.17 0.01 0.41 8.00

Apimeds Pharmaceuticals Us Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.25 8.74 14.99 9.64
APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $9.64 Mil mean?
Apimeds Pharmaceuticals Us (APUS) has a Beginning Cash Position of $9.64 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Apimeds Pharmaceuticals Us and its competitors.
Is Apimeds Pharmaceuticals Us' Beginning Cash Position too high?
Apimeds Pharmaceuticals Us' current Beginning Cash Position is $9.64 Mil. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Beginning Cash Position compare to KAYS and BIOE?
Apimeds Pharmaceuticals Us' Beginning Cash Position of $9.64 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Apimeds Pharmaceuticals Us and its competitors. Apimeds Pharmaceuticals Us's current Beginning Cash Position is $9.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Beginning Cash Position of $9.64 Mil. The current Beginning Cash Position is $9.64 Mil. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Beginning Cash Position is $9.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price